The Procter & Gamble Company Type Public (NYSE: PG) Dow Jones Industrial Average Component Industry Consumer goods Founded 1837 Headquarters Cincinnati, Ohio, U.S. Area served Worldwide Key people Bob McDonald (President) & (CEO) Products See List of Procter & Gamble brands Revenue ▲ US$79.03 billion (2009)[1] Operating income ▲ $16.13 billion (2009)[1] Net income ▲ $13.44 billion (2009)[1] Total assets ▲ $134.83 billion (2009)[1] Total equity ▲ $63.099 billion (2009)[1] Employees 127,000 (2010) Website pg.com Procter & Gamble headquarters Procter & Gamble Co. (P&G, NYSE: PG) is a Fortune 500 American multinational corporation headquartered in Downtown Cincinnati, Ohio[2] that manufactures a wide range ofconsumer goods. It is 6th in Fortune’s Most Admired Companies 2010 list.[3] P&G is credited with many business innovations including brand management and the soap opera. According to the Nielsen Company, in 2007 P&G spent more on U.S. advertising than any other company; the $2.62 billion spent by P&G is almost twice as much as that spent by General Motors, the next company on the Nielsen list.[4] P&G was named 2008 Advertiser of the Year by Cannes International Advertising Festival.[5] Procter & Gamble is a leading member of the U.S. Global Leadership Coalition, a Washington D.C.-based coalition of over 400 major companies and NGOs that advocates for a larger International Affairs Budget, which funds American diplomatic and development efforts abroad.[6] Contents [hide] 1 History 2 Operations 2.1 Management and staff 2.2 Brands…

Genentech Inc., a portmanteau of Genetic Engineering Technology, Inc., is a biotechnologycorporation, which was founded in 1976 by venture capitalist Robert A. Swanson and biochemist Dr. Herbert Boyer.[1][2] It is considered to have founded the biotechnology industry.[1][2] One of its founders, Boyer, is considered to be a pioneer in the field of recombinant DNA technology. In1973, Boyer and his colleague Stanley Norman Cohen demonstrated that restriction enzymescould be used as “scissors” to cut DNA fragments of interest from one source, to be ligated into a similarly cut plasmid vector. While Cohen returned to the laboratory in academia,[1] Swanson contacted Boyer[3] to found the company.[1] Boyer worked with Arthur Riggs and Keiichi Itakurafrom the Beckman Research Institute, and the group became the first to successfully express a human gene in bacteria when they produced the hormone somatostatin in 1977. David Goeddeland Dennis Kleid were then added to the group, and contributed to its success with synthetic human insulin in 1978. As of March 2008, Genentech employed more than 11,000 people and Arthur D. Levinson was the chairman and CEO.[4] The Swiss pharmaceutical conglomerate Hoffmann-La Roche now completely owns Genentech after completing its purchase on 26 March 2009 for approximately $46.8 billion.[5][6] Contents [hide] 1 Research 2 Facilities 3 Disputes 4 Products timeline 5 Awards and recognitions 6 References 7 External links Research Genentech markets itself as a research-driven corporation that follows the science to make new innovations. They employ more than 1,100 researchers, scientists and postdocs and cover a…

Takeda Pharmaceutical Company Limited (武田薬品工業株式会社 Takeda Yakuhin Kōgyō Kabushiki-gaisha?) (TYO: 4502) is the largest pharmaceutical company in Japan and Asia and a top 15 pharmaceutical company. The company has over 19,000 employees worldwide and achieved $15.7 billion USD in revenue during the 2008 fiscal year.[1] The company is focused onmetabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Millennium: The Takeda Oncology Company.[2] Contents [hide] 1 History 2 Locations 3 Products 4 References 5 External links History Takeda Pharmaceuticals was first founded on June 12, 1781 and was incorporated on January 29, 1925. Takeda’s Japanese logo In 1977, Takeda first entered the U.S. pharmaceutical market by developing a joint venture withAbbott Laboratories called TAP Pharmaceuticals.[3] Through TAP Pharmaceuticals, Takeda and Abbott launched the blockbusters Lupron (leuprolide) in 1985 and Prevacid (lansoprazole) in 1995.[4] One of the firm’s mainstay drugs is Actos, a compound in the thiazolidinedione class of drugs used in the treatment oftype 2 diabetes. Launched in 1999, Actos has become the best-selling diabetes drug in the world with $4 billion USD in sales during the 2008 fiscal year.[5] In February 2005, Takeda announced its acquisition of San Diego, California-based Syrrx, a company specializing in high-throughput X-ray crystallography, for $270 million.[6] In February 2008, Takeda acquired the Japanese operations of Amgen and rights to a dozen of the California biotechnology company’s pipeline…

Baxter International Inc. (NYSE: BAX), is an American health care company with headquarters in Deerfield, Illinois. The company primarily focuses on products to treathemophilia, kidney disease, immune disorders and other chronic and acute medical conditions. The company has sales of $12.3 billion, across three manufacturing divisions (BioScience, producing blood plasma proteins; Medication Delivery producing intravenous therapy products and liquids; and Renal producing equipment for dialysis and the treatment of kidney disorders).[1]The company is also involved in the production of a vaccine for the H1N1 influenza. The company was involved in several controversies. In 2001, malfunctioning dialysis machines resulted in several deaths; in 2008 the company supplied contaminated heparin; in 2009 lethalH5N1 avian flu virus was delivered to laboratories across Europe mixed with seasonal influenza vaccines; also, the company was charged with excessive billing of Kentucky Medicaid. Contents [hide] 1 History 2 Environmental activities 3 Structure 4 H1N1 vaccine 5 Controversies 5.1 Dialyzer crisis 5.2 2008 Chinese heparin contamination 5.3 2009 avian flu contamination 5.4 Kentucky settlement 5.5 2010 award over Hepatitis C infections 6 References 7 External links History Baxter International was founded in 1931 by Davis Baxter, a medical doctor, as a manufacturer and distributor of intravenous therapysolutions. Baxter’s interest was bought out in 1935 by Ralph Falk, who established a research and development function. In 1939 the company developed a vacuum-type collection container, extending the shelf life of blood from hours to weeks. In 1953…

The former Schering-Plough Corporation was a global pharmaceutical company based in theUnited States. It was founded in 1851 by Ernst Christian Friedrich Schering as Schering AG inGermany. In 1971, the Schering Corporation merged with Plough (founded by Memphis area entrepreneur Abe Plough in 1908 [1]) to form Schering-Plough. Schering-Plough manufactures several pharmaceutical drugs, the most well-known of which are the allergy drugs Claritin and Clarinex, and through a collaboration with Merck & Co., Vytorin, an anti-cholesterol drug. Schering Plough also owns and operates the major foot care brand name Dr. Scholl’s and theskin care line Coppertone. As of June 2005, Schering-Plough had 1.4% market share in the U.S., placing it seventeenth in the top twenty pharmaceutical corporations by sales compiled by IMS Health. Schering-Plough is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).[2] Contents [hide] 1 History 2 Medical products 2.1 Prescription products 2.2 Over-the-counter products 3 Veterinary products 4 Exercise drug 5 Collaborative research 6 Controversy 7 References 8 External links History Schering was founded in 1851 by Ernst Christian Friedrich Schering as Schering AG in Germany.[citation needed] Following the entry of the United States into World War II in 1941, U.S. President Franklin Delano Roosevelt ordered Schering AG’s U.S. assets be seized. These became the Schering Corporation. The company was placed under a government administratorship until 1952, when it was released and its assets sold to the private sector.[citation needed] Plough, Incorporated was founded by the Memphis, Tennessee area entrepreneur Abe…

Boehringer Ingelheim GmbH is a pharmaceutical company which concentrates on the development of human pharmaceuticals, biopharmaceuticals, chemicals, and animal health products. The Human Pharmaceuticals sector is the company’s largest division, accounting for about 96% of sales. This includes prescription medicines and consumer healthcare products. Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).[1] Contents [hide] 1 History 2 Fields of activity 2.1 Collaborative Research 3 Operational/development sites 4 Key product lines 5 See also 6 Notes 7 External links History The company was founded in 1885 during the Gründerzeit by the German chemist Dr Albert Boehringer. Initially it produced tartaric acid from wine yeast in a small factory in Ingelheim, together with 20 employees. Today, the Boehringer Ingelheim group is one of the world’s top 20 pharmaceutical companies. For many years, Boehringer Ingelheim has been one of the fastest-growing companies in the pharmaceutical industry and one of the world’s largest manufacturers of biopharmaceuticals for industrial customers. Fields of activity The business areas consist of Human Pharmaceuticals and Animal Health. In 2008, 41,300 employees were in 138 affiliated companies worldwide, research and development (R&D) facilities were in ten countries and production plants in 16 countries. Boehringer Ingelheim’s Pharma Chemicals business has pioneered the commercial production of monomers and biodegradable polymers for more than 20 years. The mission of the…

Amgen Inc. (NASDAQ: AMGN, SEHK: 4332) is an international biotechnology companyheadquartered in Thousand Oaks, California. Located in the Conejo Valley, Amgen is the world’s largest independent biotech firm. The company employs approximately 17,000 staff members. Its products include Epogen, Aranesp, Enbrel, Kineret, Neulasta, Neupogen, Sensipar / Mimpara, Nplate, and Prolia. Epogen and Neupogen (the company’s first products on the market) were the two most successful biopharmaceutical products at the time of their respective releases. BusinessWeek ranked Amgen first on the S&P 500 for being one of the most “future-oriented” of those five hundred corporations.[3] BusinessWeek ostensibly calculated the ratio of research and development spending, combined with capital spending, to total outlays; Amgen had the fourth highest ratio, at 506:1000. Amgen is the largest employer in Thousand Oaks and second only to the United States Navy in terms of number of people employed in Ventura County. With plans to expand into a new campus under construction in South San Francisco, Amgen abruptly halted construction on the plans and instead put the 365,000 square feet (33,900 m2) of new space on the sublease market.[4] It is a leading member of the U.S. Global Leadership Coalition, a coalition of over 400 companies and NGOs that promotes increased funding for US diplomatic and international development programs.[5] In 2006, Amgen began sponsoring the Tour of California, one of only three major Union Cycliste Internationale events in the United States. Contents [hide] 1 History…

For other uses, see Eli Lilly (disambiguation). Eli Lilly and Company Type Public (NYSE: LLY) Industry Pharmaceuticals, Healthcare Founded 1876 Headquarters Indianapolis, Indiana, USA Key people Sidney Taurel, Chairman John C. Lechleiter, President & CEO Derica Rice, CFO Eli Lilly, Founder Products Prozac, Humalog, Cialis, Strattera, Darvocet Revenue ▲ US$21.8 Billion (FY 2009)[1] Operating income ▲ US$5.66 Billion (FY 2009)[1] Net income ▲ US$4.33 Billion (FY 2009)[1] Total assets ▼ US$27.5 Billion (FY 2009)[2] Total equity ▲ US$9.52 Billion (FY 2009)[2] Employees 40,360 (2010) Website www.lilly.com Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company. Eli Lilly’s global headquarters is located in Indianapolis, Indiana, in the United States. The company was founded in 1876 by a pharmaceutical chemist, Eli Lilly, after whom the company was ultimately named. Among other specialties, Lilly was the first company to mass-produce penicillin and today is the world’s largest manufacturer and distributor of psychiatric medications. Contents [hide] 1 Company profile 1.1 History 2 Collaborative research 3 Pharmaceutical brands 3.1 Cialis 3.2 Cymbalta 3.3 Gemzar 3.4 Methadone 3.5 Prozac 3.5.1 Prozac in popular culture 3.6 Secobarbital 3.6.1 Secobarbital overdoses 3.7 Thimerosal 3.8 Additional Eli Lilly therapies 4 Personnel 5 Accolades 6 Controversy 6.1 Lawsuits 6.2 Criminal prosecution 7 See also 8 References 8.1 Further references 9 External links Company profile Eli Lilly and Company’s global headquarters, in Indianapolis, Indiana, United States A Fortune 500 corporation, Eli Lilly had revenues of $20 billion in 2008, making it the 148th largest company in the United States and the 10th largest…

“Squibb” redirects here. It is not to be confused with Squib. Bristol-Myers Squibb Company Type Public NYSE: BMY Industry Pharmaceuticals Founded 1887 Headquarters New York, New York Key people Lamberto Andreotti, CEO Revenue ▲ US$18.8 Billion (FY 2009)[1] Operating income ▲ US$5.34 Billion (FY 2009)[1] Net income ▲ US$10.6 Billion (FY 2009)[1] Total assets ▲ US$31.0 Billion (FY 2009)[2] Total equity ▲ US$14.8 Billion (FY 2009)[2] Employees 35,000 (2009) Website www.bms.com A Bristol-Myers Squibb R&D facility in Lawrenceville, New Jersey Bristol-Myers Squibb (NYSE: BMY), often referred to as BMS, is a pharmaceutical company, headquartered in New York City. The company was formed in 1989, following the merger its predecessors Bristol-Myers and the Squibb Corporation. Squibb was founded in 1858 by Edward Robinson Squibb in Brooklyn, New York, while Bristol-Myers was founded in 1887 byWilliam McLaren Bristol and John Ripley Myers in Clinton, New York (both were graduates ofHamilton College). Lamberto Andreotti became the company’s CEO on May 4, 2010. Former CEO James M. Cornelius remains chairman of the Board of Directors. Bristol-Myers Squibb manufactures prescription pharmaceuticals in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders. Its mission is to “discover, develop and deliver innovative medicines that help patients prevail over serious diseases.” Over the past several years BMS had been upping the price of its medicines to bolster profits….

This article is about the corporation. For other uses of the word, see Wyeth (disambiguation). Wyeth Type Subsidiary Industry Pharmaceuticals, Healthcare Founded (1860) Philadelphia,Pennsylvania, U.S. Headquarters Madison, New Jersey,  United States Key people Bernard J. Poussot, CEO, President and Vice Chairman of Wyeth Robert Essner, Chairman Joseph Mahady, President, Global Business, Wyeth Pharmaceuticals John Wyeth, Founder Products Premarin, Effexor, Enbrel, (See more products.) Revenue ▲ US$ 22.40 billion (2008) Net income ▲ US$ 4.616 billion (2008) Employees 49,732 (2005) Parent Pfizer Website www.wyeth.com Wyeth, formerly one of the companies owned by American Home Products Corporation(AHP), was one of the largest pharmaceutical companies in the world. The company was based in Madison, New Jersey, USA. They were known for manufacturing the over-the-counter (OTC) drugs Robitussin and the analgesic Advil (ibuprofen), as well as the prescription drugs Premarinand Effexor, which both boast over US$3 billion in sales annually. On January 23, 2009 The Wall Street Journal reported that Pfizer was in talks to buy Wyeth at a cost of US$68 billion.[1] On January 25, Pfizer agreed to the purchase, a deal financed with cash, shares and loans.[2] The deal was completed on October 15, 2009.[3] Contents [hide] 1 History 1.1 1860–1899 1.2 1900–1929 1.3 1930–1949 1.4 1950–1969 1.5 1970–1989 1.6 1990–1999 1.7 2000–2009 2 Divisions 2.1 Wyeth Consumer Healthcare 2.2 Wyeth Pharmaceuticals 2.3 Fort Dodge Animal Health 3 Products 3.1 Wyeth Consumer Healthcare Products 3.2 Wyeth Pharmaceuticals Products 3.3 Fort Dodge Animal Health Products 3.4 Wyeth Milk…

Abbott Laboratories (NYSE: ABT) is a pharmaceuticals health care company. It has 72,000 employees and operates in over 130 countries.[3] The company headquarters are in Abbott Park,Illinois, located near North Chicago, Illinois. Abbott Laboratories was founded by Chicago physician Wallace Calvin Abbott in 1888. In 2008, Abbott had over $29 billion in revenue. In 1985, the company developed the first HIV blood screening test. The company’s drug portfolio includes Humira, a drug for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis,Crohn’s disease, moderate to severe chronic psoriasis and juvenile idiopathic arthritis; Norvir, a treatment for HIV; Depakote, an anticonvulsant drug; and Synthroid, a synthetic thyroid hormone. Abbott also has a broad range of medical devices, diagnostics and immunoassayproducts as well as nutritional products, including Ensure, a line of well known meal replacement shakes, and EAS, the largest producer of performance based nutritional supplements. Abbott’s in vitro diagnostics business is a world leader in immunoassays and blood screening. Abbott’s broad range of medical tests and diagnostic instrument systems are used worldwide by hospitals, laboratories, blood banks, and physician offices to diagnose and monitor diseases such as HIV, hepatitis, cancer, heart failure and metabolic disorders, as well as assess other important indicators of general health. Abbott Point-of-Care manufactures diagnostic products for blood analysis to provide health care professionals critical diagnostics information accurately and immediately at the point of patient care. In addition…

This article needs additional citations for verification. Please help improve this article by adding reliable references. Unsourced material may be challenged and removed.(March 2010) Merck & Co., Inc. (Merck Sharp & Dohme (MSD) outside the United States and Canada) Type Public (NYSE: MRK) Dow Jones Industrial Average Component Industry Pharmaceuticals Founded 1891 as a subsidiary of Merck KGaA 1917 as an independent company Headquarters Whitehouse Station, New Jersey, United States Key people Richard T. Clark, Chairman, President & CEO Stanley F. Barshay, EVP and president, Consumer Health Care Richard S. Bowles, Ph.D., chief compliance officer Willie A. Deese, EVP and president, Merck Manufacturing Kenneth C. Frazier, EVP and president, Global Human Health Mirian Graddick-Weir, Ph.D., EVP, Human Resources Peter N. Kellogg, chief financial officer Peter S. Kim, Ph.D., EVP and president, Merck Research Laboratories Raul E. Kohan, president, Animal Health Bruce N. Kuhlik, general counsel J. Chris Scalet, chief information officer, Global Services Mervyn Turner, Ph.D, chief strategy officer Products Gardasil Singulair Propecia/Proscar Zocor Vioxx Fosamax See more complete products listing. Revenue ▲ US$27.4 Billion (FY 2009)[1] Operating income ▲ US$4.83 Billion (FY 2009)[1] Net income ▲ US$12.9 Billion (FY 2009)[1] Total assets ▲ US$112 Billion (FY 2009)[2] Total equity ▲ US$59.1 Billion (FY 2009)[2] Employees 61,500 (2005) Website merck.com Merck & Co., Inc. (NYSE: MRK), also known as Merck Sharp & Dohme or MSD outside theUnited States and Canada, is one…

This article needs additional citations for verification. Please help improve this article by adding reliable references. Unsourced material may be challenged and removed.(October 2009) AstraZeneca plc Type Public limited company (LSE: AZN,NASDAQ: AZN,OMX: AZN) Industry Pharmaceutical Founded 6 April 1999 by merger Headquarters London, United Kingdom Key people Louis Schweitzer, Chairman David R. Brennan, Chief Executive Officer Products Pharmaceutical products for humans Revenue $32,804 million (2009)[1] Operating income $11,543 million (2009)[1] Net income $7,544 million (2009)[1] Total assets ▼ US$46.8 Billion (FY 2009)[2] Total equity ▲ US$15.9 Billion (FY 2009)[2] Employees 62,000 (2010)[3] Website astrazeneca.com AstraZeneca plc[4] (LSE: AZN, NYSE: AZN, OMX: AZN) is a global pharmaceutical andbiologics company headquartered in London, United Kingdom. It is the world’s seventh largest pharmaceutical company measured by revenues and has operations in over 100 countries.[5][6] It has a portfolio of products for major disease areas including cancer, cardiovascular,gastrointestinal, infection, neuroscience, respiratory and inflammation.[3] Its primary listing is on the London Stock Exchange and it is a constituent of the FTSE 100 Index. It has secondary listings on the New York Stock Exchange and the OMX exchange. Contents [hide] 1 History 2 Operations 3 Products 4 Controversies 4.1 Seroquel: adverse effects and trial procedures 4.2 Late-stage trial failures 4.3 MedImmune takeover 4.4 Nexium 4.5 Malaria drugs 4.6 Corporate sexual harassment 4.7 Bildman fraud 4.8 Nobel Prize investigation 2008 4.9 Transfer mispricing 5 Senior management 6 See also 7 References 8 External links [edit]History Astra AB was founded in 1913 by 400 doctors and apothecaries in Södertälje, Sweden.[7] In 1949 the company developed Xylocaine, a local anesthetic.[clarification needed] In 1994 the company formed a joint venture with Merck to…

F. Hoffmann–La Roche Ltd. is a Swiss global health-care company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange (SIX: ROG). The company headquarters are located in Basel and the company has many sites around the world – including: Nutley, NJ, Palo Alto, California, Pleasanton, Branchburg, Fishers, Indiana,Florence, South Carolina, Boulder, Colorado and Ponce, Puerto Rico in the US, Welwyn Garden City and Burgess Hill in the UK, Clarecastle in Ireland, Mannheim and Penzberg in Germany,Mississauga and Laval in Canada, and Shanghai in China. The company also owns the American biotechnology company Genentech, which is a wholly owned subsidiary, and the Japanese biotechnology company Chugai Pharmaceuticals as well as the Tucson, Arizona based Ventana. Roche’s revenues during fiscal year 2008 were CHF 49.05 billion.[1] Descendants of the founding Hoffmann and Oeri families own half of the company.[1] Swiss pharma firm Novartis owns 33% of the company.[1] F. Hoffmann–La Roche is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).[3] Contents [hide] 1 History 2 Creation of the first anti-depressant 3 Vitamin price fixing 4 Products 5 Oseltamivir Controversy 6 Collaborative research 7 Additional key persons 8 Bibliography 9 References 10 External links [edit]History Founded in 1896 by Fritz Hoffmann-La Roche, the company was early on known for producing various vitamin preparations and derivatives. In 1934, it became the first company to mass produce synthetic vitamin C, under the brand name Redoxon. In 1957 it introduced the class oftranquilizers known as benzodiazepines (with Valium and Rohypnol being the best known…

Sanofi-Aventis (Euronext: SAN, NYSE: SNY), headquartered in Paris, France, is a multinational pharmaceutical company, the world’s fourth-largest by prescription sales.[2][3]Sanofi-Aventis engages in the research and development, manufacturing and marketing of pharmaceutical products for sale principally in the prescription market, but the firm also developsover-the-counter medication. Sanofi-Aventis covers 7 major therapeutic areas: cardiovascular,central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines (it is the world’s largest producer of the latter through its subsidiary Sanofi Pasteur).[4] The company is a full member of the European Federation of Pharmaceutical Industries and Associations(EFPIA).[5] Contents [hide] 1 History 1.1 Sanofi-Aventis 1.2 Sanofi-Synthélabo 1.3 Aventis 2 Business 2.1 Products 2.2 Management 2.3 Stockholders 3 Collaborative research 4 Aventis Foundation 5 See also 6 References 7 External links ]History []Sanofi-Aventis This article needs additional citations for verification. Please help improve this article by adding reliable references. Unsourced material may be challenged and removed. (April 2009) Sanofi-Aventis was formed in 2004 when Sanofi-Synthélabo acquired Aventis. In early 2004, Sanofi-Synthélabo made a hostile takeover bid worth €47.8 bn for Aventis. Initially, Aventis rejected the bid because it felt that the bid offered inferior value based on the company’s share value. The three-month takeover battle concluded when Sanofi-Synthélabo launched a friendly bid of €54.5 bn in place of the previously rejected hostile bid. French government intervention also played an active role. The French government, desiring what they called a “local solution”, put heavy pressure on Sanofi-Synthélabo to raise…

Not to be confused with S.C. Johnson. Johnson & Johnson   Type  Public (NYSE: JNJ) Dow Jones Industrial Average Component Industry  Major drugs Health care Soaps Shampoos Founded 1886 Founder(s) Robert Wood Johnson I James Wood Johnson Edward Mead Johnson Headquarters New Brunswick, NJ, U.S. Area served Worldwide Key people William C. Weldon (Chairman) & (CEO) Products Pharmaceuticals Medical devices Health care products Toiletries Soaps Shampoos, etc. Revenue ▲ US$61.9 Billion (FY 2009)[1] Operating income ▲ US$15.7 Billion (FY 2009)[1] Net income ▲ US$12.3 Billion (FY 2009)[1] Total assets ▲ US$94.7 Billion (FY 2009)[2] Total equity ▲ US$50.6 Billion (FY 2009)[2] Employees 118,700 (2009)[3] Website JNJ.com also JJ.com Johnson & Johnson (NYSE: JNJ) is a global American pharmaceutical, medical devices and consumer packaged goods manufacturer founded in 1886. Its common stock is a component of the Dow Jones Industrial Average and the company is listed among the Fortune 500. Johnson & Johnson is known for its corporate reputation, consistently ranking at the top of Harris Interactive‘s National Corporate Reputation Survey,[4] ranking as the world’s most respected company by Barron’s Magazine,[5] and was the first corporation awarded the Benjamin Franklin Award for Public Diplomacy by the U.S. State Department for its funding of…

GlaxoSmithKline plc (LSE: GSK NYSE: GSK), often abbreviated to GSK, is a global pharmaceutical, biologics, vaccines and consumer healthcare company headquartered in London, United Kingdom. It is the world’s third largest pharmaceutical company measured by revenues (after Johnson & Johnson and Pfizer).[3] It has a portfolio of products for major disease areas including asthma, cancer, virus control, infections, mental health, diabetes and digestive conditions.[4] It also has a large consumer healthcare division which produces and markets oral healthcare products, nutritional drinks and over-the-counter medicines, including Sensodyne, Horlicks and Gaviscon.[4] Its primary listing is on the London Stock Exchange and it is a constituent of the FTSE 100 Index. It has a secondary listing on the New York Stock Exchange. Contents [hide] 1 History 1.1 GlaxoWellcome 1.2 SmithKline Beecham 1.3 Recent developments 2 Operations 3 Products 4 Initiatives to eradicate disease 5 Global locations 6 Corporate governance 7 Diversity 8 Controversy 8.1 Legal 8.1.1 Paroxetine 8.1.2 Ribena 8.1.3 Avandia 9 Announced policy change 10 See also 11 References 12 External links History Former GlaxoSmithKline building in Hamburg, Germany GSK was formed in 2000 by the merger of GlaxoWellcome plc (formed from the acquisition of Wellcome plc by Glaxo plc), and SmithKline Beecham…

This article is about the chemical and pharmaceutical company. For other uses, see Bayer (disambiguation). Not to be confused with Beyer. Bayer AG Type  Public (FWB: BAYN, TYO: 4863) Industry  Pharmaceuticals, chemicals Founded 1863 Founder(s)  Friedrich Bayer, Johann Friedrich Weskott Headquarters Leverkusen, Germany Key people Werner Wenning (CEO), Manfred Schneider (Chairman of the supervisory board) Products  Veterinary drugs, diagnostic imaging, general and specialty medicines, women’s health products, over-the-counter drugs, diabetes care, pesticides, plant biotechnology, polymers, coatings, adhesives Revenue  €31.168 billion (2009)[1] Operating income  ▲ €3.006 billion (2009)[1] Profit  ▲ €1.359 billion (2009)[1] Employees  108,400 (2009)[1] Subsidiaries  Bayer MaterialScience, Bayer USA, Bayer Schering Pharma, Bayer HealthCare Pharmaceuticals, Bayer CropScience Website  www.bayer.com Bayer AG (German pronunciation: [ˈbaɪə]) (FWB: BAYN, TYO: 4863) is a chemical and pharmaceutical company founded in Barmen, Germany in 1863. Today it is headquartered in Leverkusen, North Rhine-Westphalia, Germany. It is well-known for its original brand of aspirin.   History Advertisement for Aspirin, Heroin, Lycetol, Salophen Bayer AG was founded in Barmen (today a part of Wuppertal), Germany in 1863 by Friedrich Bayer and his partner, Johann Friedrich Weskott. Bayer’s first major product was acetylsalicylic acid (originally discovered by French chemist Charles Frederic Gerhardt in 1853), a modification of salicylic…

Novartis International AG is a multinational pharmaceutical company based in Basel, Switzerland, ranking number three in sales among the world-wide industry, which accounted 36.173 billon in 2008.[3] It currently is the sixth largest pharmaceutical company in terms of revenue ($41.5 billion in 2009) with a profit margin of about 20%, which is the same as its industry competitors. Their profits were down by 31% from 2007 levels.[4] Novartis manufactures drugs such as clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate (Gleevec / Glivec), ciclosporin (Neoral / Sandimmun), letrozole (Femara), methylphenidate (Ritalin), terbinafine (Lamisil), and others. Renamed to Novartis following an acquisition by Ciba-Geigy, it owns Sandoz, a large manufacturer of generic drugs. The company formerly owned the Gerber Products Company, a major infant and baby products producer, but sold it to Nestlé on 1 September 2007.[5][6][7][8] Novartis is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) [9] and of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) [10]   Collaborative research In addition to internal research and development activities Novartis is also involved in publicly funded collaborative research projects, with other industrial and academic partners. One example in the area of non-clinical…